T2D-2, retatrutide lowered A1C 2.2 points vs 1.8 with semaglutide 2 mg and more than doubled weight loss at 80 weeks.
At AMCP Nexus 2026, Susan M. Wescott, RPh, MBA, discussed how health plans evaluate rare disease therapies amid limited data and high costs.
A poster at the ASCO Quality Care Symposium describes how a value-based care partnership used prior authorization data and ...
About one quarter of patients with overactive bladder were taking their initial oral regimen at nearly 3 years, yet most ...
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access ...
James D. Chambers, PhD, MPharm, MSc, discusses US biosimilar adoption and opportunities to expand patient access and lower ...
Sputum is considered a noninvasive marker of airway inflammation, and its color is an indicator of bronchiectasis disease ...
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs ...
Data presented at ESMO Congress 2026 show lifileucel met its feasibility end point in refractory sarcoma, with 80% disease ...
NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for ...
Fewer than two-thirds of patients prescribed augmentation begin infusions, and half of starters miss doses. Structured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results